To prepare for potential FDA authorization, AMA has released new CPT codes for pediatric doses of the Pfizer COVID-19 vaccine.

he American Medical Association (AMA) has issued new Current Procedural Terminology (CPT) codes for pediatric doses of the Pfizer COVID-19 vaccine.

In September 2021, Pfizer and BioNTech shared the results of a Phase 2/3 clinical trial in which two doses of the vaccine elicited a strong immune response in children ages 5 to 11. Following the trial, the companies submitted the data to the Food and Drug Administration (FDA).

Pfizer recently announced that they have submitted a formal request to the FDA for emergency use authorization of their COVID-19 vaccine in children ages 5 to 11.

In August 2021, the FDA granted full approval of the Pfizer-BioNTech vaccine for individuals 16 and older.

The AMA updated the COVID-19 vaccine CPT codes to ensure preparedness if the FDA approves Pfizer’s two-dose pediatric vaccine. The early publication may help healthcare professionals prepare their electronic health record systems ahead of the potential authorization.

The CPT codes for the pediatric Pfizer COVID-19 vaccine are as follows:

  • 91307: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
  • 0071A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose
  • 0072A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose 

“The AMA supports the goal of extending COVID-19 immunization protection to a broader age range of children,” Gerald Harmon, MD, AMA president, stated in the press release. “A rigorous, transparent review process by the Federal Drug Administration and Centers for Disease Control and Prevention will examine the safety and efficacy of Pfizer’s COVID-19 vaccine for potential use in children between ages 5 and 11.”

Specific CPT codes for each variation of the COVID-19 vaccine can help healthcare professionals distinguish between doses and assist in data collection.

The AMA first added COVID-19 vaccine codes to the CPT code set in November 2020 to help providers report immunizations. The Association has since issued CPT codes for Pfizer, Moderna, AstraZeneca, Johnson & Johnson, and Novavax. The AMA updated the code set to include third dose codes for Pfizer and Moderna, as well.

Short, medium, and long descriptors for all COVID-19 vaccine and administration CPT codes are available on the AMA website. Any code set changes relating to COVID-19 can also be found on the website.